# CORXEL Pharmaceuticals funding rounds and investors

As of 14 Oct 2026, CORXEL Pharmaceuticals has raised $287M across 1 verified round on record; latest: $287 million Series D+, announced 22 Jan 2026.

Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus.

Website: https://corxelbio.com  
Page: https://fireround.dev/companies/corxelbio.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-01-22 | Series D+ | $287 million | not stated | Adage Capital Management, HBM Healthcare Investments, Hengdian Group Capital, Invus, RA Capital Management, RTW Investments, SilverArc Capital, SR One, SymBiosis, TCGX | [globenewswire.com](https://www.globenewswire.com/news-release/2026/01/22/3223696/0/en/corxel-announces-287-million-series-d1-financing-to-further-advance-its-cardiometabolic-pipeline-including-oral-small-molecule-glp-1-receptor-agonist.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.